Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5216054 | 0.95 | ACHE (0.38) | ACHEOPRM1OPRD1F11KLKB1 | |
| Trifluoroacetic Acid SCHEMBL7423644 | 0.94 | ACHE (0.39) | ACHEOPRM1OPRD1OPRK1ADRA2C | |
| Trifluoroacetic Acid SCHEMBL5210906 | 0.89 | ACHE (0.39) | ACHEOPRM1OPRD1F11KLKB1 | |
| Trifluoroacetic Acid SCHEMBL7426179 | 0.86 | F2 (0.36) | OPRM1OPRD1OPRK1ADRA2C | |
| Trifluoroacetic Acid SCHEMBL7428691 | 0.85 | CFD (0.43) | ACHEKLKB1KDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL7422801 | 0.84 | ACHE (0.35) | ACHEOPRM1OPRD1F11OPRK1 | |
| Trifluoroacetic Acid SCHEMBL8040508 | 0.84 | F2 (0.34) | OPRM1OPRD1OPRK1ADRA2C | |
| Trifluoroacetic Acid SCHEMBL5210467 | 0.81 | F2 (0.37) | OPRM1OPRD1OPRK1ADRA2C | |
| Trifluoroacetic Acid SCHEMBL4809174 | 0.79 | RXRA (0.37) | OPRM1OPRD1KDM4E | |
| Trifluoroacetic Acid SCHEMBL5213937 | 0.79 | F2 (0.34) | OPRM1OPRD1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ACHE 1165/4885OPRM1 1789/4885OPRD1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.